Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis

about

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Item

http://www.wikidata.org/entity/Q57825312

description

scientific article published on 15 March 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2018

@uk

name

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@en

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@nl

type

Item

label

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@en

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@nl

prefLabel

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@en

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@nl

P1476

Adjuvant Antiangiogenic Agents ...... matic Review and Meta-analysis

@en

P2093

Belal Firwana

http://www.w3.org/2001/XMLSchema#string

Diana Almader-Douglas

http://www.w3.org/2001/XMLSchema#string

Richard W Joseph

http://www.w3.org/2001/XMLSchema#string

Thai H Ho

http://www.w3.org/2001/XMLSchema#string

Zhen Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Indirect comparisons of competing interventions

Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Adjuvant therapy in renal cell carcinoma-past, present, and future.

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Cancer Statistics, 2017.

P304

101-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EUO.2018.03.012

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Talal Hilal

Mohamad Bassam Sonbol

P577

2018-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30345423

http://www.w3.org/2001/XMLSchema#string

P932

6192050

http://www.w3.org/2001/XMLSchema#string